Neurocrine Biosciences (NBIX) Misses Q1 EPS by 5c
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $0.30, $0.05 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $310.6 million versus the consensus estimate of $304.19 million.
Reiterated 2022 INGREZZA Sales and Operating Expense Guidance:
Range | |||
(in millions) | Low | High | |
INGREZZA Net Product Sales 1 | $ 1,250 | $ 1,350 | |
GAAP R&D expense 2 | $ 380 | $ 415 | |
Non-GAAP R&D expense 3 | $ 325 | $ 360 | |
GAAP SG&A expense | $ 720 | $ 735 | |
Non-GAAP SG&A expense 3 | $ 605 | $ 620 | |
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.